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CRISPRs and Cas proteins constitute an RNA-
guided microbial immune system against invading
nucleic acids. Cas1 is a universal Cas protein found
in all three types of CRISPR-Cas systems, and
its role is implicated in new spacer acquisition dur-
ing CRISPR-mediated adaptive immunity. Here, we
report the crystal structure of Streptococcus pyo-
genesCas1 (SpCas1) in a type II CRISPR-Cas system
and characterize its interaction with S. pyogenes
Csn2 (SpCsn2). The SpCas1 structure reveals a
unique conformational state distinct from type I
Cas1 structures, resulting in a more extensive dimer-
ization interface, a more globular overall structure,
and a disruption of potential metal-binding sites for
catalysis. We demonstrate that SpCas1 directly in-
teracts with SpCsn2, and identify the binding inter-
face and key residues for Cas complex formation.
These results provide structural information for a
type II Cas1 protein, and lay a foundation for studying
multiprotein Cas complexes functioning in type II
CRISPR-Cas systems.
INTRODUCTION
Clustered regularly interspaced short palindromic repeats
(CRISPRs) and CRISPR-associated (Cas) proteins constitute
an RNA-guided microbial immune system against invading
foreign nucleic acids (Sorek et al., 2013; van der Oost et al.,
2014;Wiedenheft et al., 2012). CRISPRs are repetitive genetic el-
ements found in bacterial and archaeal genomes, and consist of
short invariable ‘‘repeat’’ sequences interspaced with variable
‘‘spacer’’ sequences. In the adaptation stage of CRISPR-medi-
ated immunity, fragments of foreign nucleic acids are integrated
into CRISPR loci of the host genome as variable spacers. Then
the CRISPR loci are transcribed and processed to generate70 Structure 24, 70–79, January 5, 2016 ª2016 Elsevier Ltd All rightsCRISPR RNAs (crRNAs) containing a single spacer sequence
during the expression stage. Finally, during the interference
stage the crRNAs are used as a guide for degrading reinvading
foreign nucleic acids. All of these events are mediated by Cas
proteins, which are encoded by cas genes found adjacent to
CRISPR loci (Gasiunas et al., 2014; Jackson and Wiedenheft,
2015; Jiang and Doudna, 2015; Plagens et al., 2015; Reeks
et al., 2013; Tsui and Li, 2015).
CRISPR-Cas systems can be classified into threemajor types,
types I, II, and III, with a further division into more than ten
subtypes (Chylinski et al., 2014; Makarova et al., 2011). Cas1 is
a universal Cas protein found in all three types of CRISPR-Cas
systems, and its role is implicated in new spacer acquisition dur-
ing the adaptation stage of CRISPR-mediated immunity (Makar-
ova et al., 2011; van der Oost et al., 2014). Several Cas1 proteins
from type I CRISPR-Cas systems have been structurally and
functionally characterized, including those from Pseudomonas
aeruginosa, Escherichia coli, and Archaeoglobus fulgidus
(PaCas1, EcCas1, and AfCas1, respectively) (Babu et al., 2011;
Kim et al., 2013; Wiedenheft et al., 2009). These type I Cas1 pro-
teins share a butterfly-like homodimeric structure with each
monomer containing two distinct domains, and exhibit metal-
dependent nuclease activities. Three conserved residues (two
carboxylates and one histidine), found within close proximity
(<4 A˚) in the structures, have been determined to be critical for
catalysis (Babu et al., 2011; Kim et al., 2013; Wiedenheft et al.,
2009).
It has been reported that Cas proteins form multiprotein com-
plexes, which play crucial roles in CRISPR-mediated immunity.
In type I and III CRISPR-Cas systems, crRNAs associate with
multiple Cas proteins to form RNA-guided interference com-
plexes, also known as Cascade (CRISPR-associated complex
for antiviral defense) complexes (Jiang and Doudna, 2015; van
der Oost et al., 2014). In the E. coli type I CRISPR-Cas system,
Cas1 and Cas2 form a stable complex that mediates spacer
acquisition during the adaptation stage of CRISPR-mediated
immunity (Nunez et al., 2014, 2015). Although a single multi-
functional Cas protein, Cas9, is responsible for the interference
step in type II CRISPR-Cas systems (Deltcheva et al., 2011),
it has recently been shown that, in Streptococcus pyogenes,reserved
Figure 1. Crystal Structure of SpCas1
(A) Representation of the S. pyogenes type II CRISPR-Cas locus.
(B) Monomeric structure of SpCas1. N- and C-terminal domains of chain A are
shown in green and cyan, respectively. Secondary structure elements are also
indicated.
Table 1. Data Collection, Phasing, and Refinement Statistics
Space group P3121
Unit cell parameters (A˚) a = b = 95.21, c = 210.84
Wavelength (A˚) 0.9794
Data Collection
Resolution range (A˚) 50.00–2.25 (2.33–2.25)
No. of reflections 53,138 (5,224)




Mean I/s 21.2 (3.9)
Phasing
f0, f00 used in phasing 8.0, 6.1
Figure of merit 0.367
Refinement




RMSD bonds (A˚) 0.019
RMSD angles () 1.760
Average B factor (A˚2) 70.77
No. of water molecules 249
Ramachandran favored (%) 96.3
Ramachandran allowed (%) 3.5
Values in parentheses are for the highest-resolution shell.
aRmerge = ShSjIi(h)  <I(h)>j/ShSiIi(h), where Ii(h) is the intensity of an indi-
vidual measurement of the reflection and <I(h)> is the mean intensity of
the reflection.
bRcryst = ShjjFobsjjFcalcjj/ShjFobsj, where Fobs and Fcalc are the observed
and calculated structure factor amplitudes, respectively.
cRfree was calculated as Rcryst using 5% of the randomly selected
unique reflections that were omitted from structure refinement.Cas9 associates with other Cas proteins (Cas1, Cas2, and Csn2)
involved in spacer acquisition (Heler et al., 2015). This suggests
that a multiprotein Cas complex may have an important function
in type II CRISPR-Cas systems; however, no structural and
biochemical analysis of the type II Cas complex has been re-
ported. The S. pyogenes type II CRISPR-Cas system has been
of particular interest, since its Cas9 protein (SpCas9) is a core
component of a recently developed revolutionary genome-edit-
ing tool for biological and medical sciences (Doudna and Char-
pentier, 2014).
In this study, we determine the crystal structure ofS. pyogenes
Cas1 (SpCas1) and show its direct interaction with S. pyogenes
Csn2 (SpCsn2), another Cas protein that functions in spacer
acquisition of type II CRISPR-Cas systems (Figure 1A) (Heler
et al., 2015; Koo et al., 2012; Wei et al., 2015). Previous structural
and functional studies revealed that the Csn2 protein has a tetra-
meric ring-shaped structure (Ellinger et al., 2012; Koo et al.,
2012; Lee et al., 2012; Nam et al., 2011) and exhibits double-
stranded DNA (dsDNA) end-binding and sliding activities
through its central hole (Arslan et al., 2013). The unique confor-
mational state of SpCas1 creates a more compact and globular
overall structure with a more extensive dimerization interface,
which results in the disruption of a potential metal-binding site
for catalysis. We also demonstrate that SpCas1 forms a complex
with SpCsn2 by using size-exclusion chromatography and
isothermal titration calorimetry (ITC). In silico docking simulation
followed by binding experiments with mutant proteins further
identified a potential binding interface and key residues for com-Structure 24plex formation. Taken together, our results present structural in-
formation about a type II Cas1 protein, and provide insight into a
multiprotein Cas complex that functions in the adaptive immunity
of type II CRISPR-Cas systems.
RESULTS
SpCas1 Exhibits Unique Structural Features that Are
Distinct from Type I Homologs
The crystal structure of SpCas1 was determined to a resolution
of 2.25 A˚ using single-wavelength anomalous diffraction. Data
collection and refinement statistics are summarized in Table 1.
The asymmetric unit contains two SpCas1 molecules forming
a single dimer with a pseudo-two-fold symmetry. The root-
mean-square deviation (RMSD) value of Ca atomic positions
between the two SpCas1 monomers is 0.8 A˚. Several residues
(residues 83–87 in chain A, and residue 1 in chain B) were not
included in the final model due to insufficient electron density.
The crystal structure of SpCas1 displays the same two-
domain architecture as observed in type I Cas1 structures
despite low sequence identities (<20%) (Figures 1B and 2). The
SpCas1 monomer consists of an N-terminal b-sandwich-like
domain (residues 1–81) and a C-terminal a-helical domain (resi-
dues 88–289) connected by a flexible linker (residues 82–87)., 70–79, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 71
Figure 2. Dimerization of SpCas1
(A) Dimeric structure of SpCas1. N- andC-terminal
domains of chain A are colored as in Figure 1.
Chain B is shown in yellow.
(B) SpCas1 dimerization interface between C-ter-
minal domains. The 2mFobs  DFcalc map is con-
toured at 1.0s for residues at the interface.Topology and domain folds of SpCas1 are similar to those of the
type I Cas1 proteins. The N-terminal domain comprises two four-
stranded mixed b sheets (b1, b5, b7, b8, and b2–b4, b6) and two
helices (h1, a1). The C-terminal domain includes nine a helices
(a2–a10), three 310 helices (h2–h4), and two short b strands
(b9, b10). The individual domains of SpCas1 are superposed
well with the respective domains of the previously solved type I
Cas1 structures (Figure S1). The RMSD values of Ca atomic po-
sitions for the N- and C-terminal domains between SpCas1 and
AfCas1, which exhibits the highest similarity in sequence and
structure among the available type I Cas1 structures (Figure 3A),
are 2.0 and 2.3 A˚, respectively.
Strikingly, despite the similarity in the domain folds, the relative
orientation of the two domains within a SpCas1 monomer is
distinct from those seen in the type I Cas1 structures, resulting
in a significant change in its conformation (Figure 3B). When
SpCas1 and AfCas1 monomers were aligned based on their
N-terminal domains, a substantial deviation was noted in the
positioning of their C-terminal domains. It appears that the C-ter-
minal domains can rotate (50), using the N-terminal domains
as a fixed point. Thus, the RMSD value of Ca atomic positions
between the full-length SpCas1 and AfCas1 monomers is signif-
icantly higher (4.9 A˚) than those calculated separately for the N-
and C-terminal domains.
The unique monomeric conformation of SpCas1 creates a
dimeric interface that is distinct from those in type I homologous
structures (Figures 2B and 3C). The type I Cas1 dimers are
mainly assembled by interaction of the two N-terminal domains
involving residues in, or adjacent to, three secondary structural
elements (b6, a1, b8). On the other hand, in the crystal structure
of SpCas1 we observed another major dimeric interface formed
by its two C-terminal domains in addition to the conserved N-ter-
minal interactions. The loop connecting a6 and a7 in the C-termi-
nal domain of SpCas1 makes extensive contact with residues on
the concave surface formed by helices (a5–a8) of the other C-ter-
minal domain of the dimer. The interactions between the two
SpCas1 C-terminal domains form 19 hydrogen bonds and bury
2,707 A˚2 of surface area, while the dimerization of AfCas1 results
in only four hydrogen bonds and 869 A˚2 of buried surface area
between its C-terminal domains. This illustrates that SpCas1 dis-
plays a more extensive dimerization interface between C-termi-
nal domains than the type I Cas1 structures.72 Structure 24, 70–79, January 5, 2016 ª2016 Elsevier Ltd All rights reservedThe overall structure of SpCas1 is
significantly different from those of the
type I Cas1 proteins (Figure 3C). The
shape of type I Cas1 dimers has been
described previously as a butterfly, in
which the N- and C-terminal domains
represent the hindwing and forewing,
respectively (Wiedenheft et al., 2009). InSpCas1, it appears that its C-terminal domains make more
extensive contact, and slide into the center of the structure
against each other. The wingspan of SpCas1 is only 65 A˚
whereas AfCas1 has a wingspan of 102 A˚. This indicates that
SpCas1 has a more globular and compact dimeric structure
compared with the type I homologs (Figure 3C).
Disruption of Potential Catalytic Metal-Binding Sites in
SpCas1
The type I Cas1 proteins have been reported to cleave various
nucleic acid substrates in sequence-independent and metal-
dependent manners (Babu et al., 2011; Kim et al., 2013; Wieden-
heft et al., 2009). These Cas1 proteins have, in common, divalent
metal ion-dependent nuclease activities against dsDNAs (Babu
et al., 2011; Kim et al., 2013; Wiedenheft et al., 2009). Three
conserved residues (two carboxylates and one histidine) in the
C-terminal domain have been identified to be important for the
activity, and in PaCas1 they coordinate a catalytic manganese
ion (Figure 4A, bottom) (Wiedenheft et al., 2009). In the other
type I Cas1 structures no metal ion was found, but the positions
of the three residues are structurally conserved (Figure 4A, mid-
dle) (Babu et al., 2011; Kim et al., 2013). In previous studies,
mutating any of these three residues or adding EDTA inhibited
the catalytic activity (Babu et al., 2011; Kim et al., 2013; Wieden-
heft et al., 2009).
In SpCas1 and other type II Cas1 homologs, the residues
(E149, H205, and E220 in SpCas1) are conserved in sequence
(Figure S2), but in the SpCas1 structure they are not found within
close proximity (Figure 4A, top, and Figure S3). The histidine res-
idue is located further away from the two glutamate residues in
both SpCas1 monomers. Moreover, the side chain of Q208 in
chain B is found in the space between the three conserved res-
idues of chain A, occupying the potential metal-binding site in the
SpCas1 monomer. This suggests that the more extensive con-
tact between two C-terminal domains of SpCas1 leads to the
disruption of the potential catalytic metal-binding site. In fact,
no significant amount of metal ion was co-purified with SpCas1,
as measured by inductively coupled plasma mass spectrometry
(Table S1).
In addition to structural rearrangement of the three residues,
the unique conformational state of SpCas1 results in the burial
of potential metal-binding sites. Despite the separation of
Figure 3. Sequence and Structure Comparison of Type I and II Cas1 Homologs
(A) Structure-based sequence alignment of SpCas1 and type I Cas1 proteins. Secondary structure elements are indicated based on SpCas1. Three conserved
residues coordinating a metal ion for catalysis in type I PaCas are marked with red triangles. SpCas1 residues predicted to participate in electrostatic interactions
with SpCsn2 are indicated by blue triangles.
(B) Structural alignment of SpCas1 and AfCas1 monomers based on their N-terminal domains. SpCas1 is colored as in Figure 2, and AfCas1 is shown in pink.
(C) Side-by-side comparison of SpCas1 (left) and AfCas1 (right) dimeric structures. SpCas1 is colored as in Figure 2, and AfCas1 is shown in pink and orange,
representing two different monomers.H205, the two SpCas1 glutamate residues (E149 and E220)
become significantly buried upon dimerization while the surface
areas of the corresponding glutamate residues in the type I Cas1
structures are not affected by their dimeric assemblies (Table
S2). The distance between the two potential metal-binding sites
of SpCas1 is only15 A˚, whereas that of AfCas1 is43 A˚. These
observations suggest limited accessibility of the SpCas1 sites,
particularly for large substrates such as dsDNAs. Thus, it is un-
likely that the potential metal-binding sites in SpCas1 are
responsible for the binding and/or cleavage of dsDNAs unless
a significant conformational change occurs.
To confirm whether the catalytic function is conserved in
SpCas1, we performed nuclease activity assays for SpCas1 us-
ing various nucleic acid substrates. First, we examined its
dsDNA nuclease activity against linearized pUC19 plasmids
with various divalent ions, but no cleavage was detected (Fig-
ure 4B, top). Its nuclease function was also tested for a moreStructure 24specific dsDNA substrate containing the S. pyogenes type II
CRISPR sequence, but we did not detect activity in this assay
(Figure 4B, bottom). With other types of nucleic acid substrates
including single-stranded DNAs, double-stranded RNAs, and
single-stranded RNAs, SpCas1 did not display any nuclease ac-
tivity under the conditions used (Figure S3). Our results suggest
that the SpCas1 may not have a nuclease activity against the
tested nucleic acid substrates, although we cannot exclude
the possibility that more specific experimental conditions may
be required for its catalytic function.
SpCas1 Interacts Directly with SpCsn2 to Form a
Multiprotein Cas Complex
Csn2 is a type II-specific Cas protein involved in the spacer
acquisition process during CRISPR-mediated immunity (Barran-
gou et al., 2007; Heler et al., 2015; Wei et al., 2015). We previ-
ously determined the crystal structure of SpCsn2 and revealed, 70–79, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 73
Figure 4. Disruption of Potential Catalytic Metal-Binding Sites in
SpCas1
(A) Close-up view of three conserved residues in the potential metal-binding
site in SpCas1 (top), AfCas1 (middle), and PaCas1 (bottom). SpCas1 and
AfCas1 are colored as in Figure 3. PaCas1 is shown in brown, and the bound
manganese ion is represented by a purple sphere.
(B) Test of dsDNA cleavage by SpCas1. Linearized pUC19 plasmids (top) and
PCR products containing the S. pyogenes type II CRISPR sequence (bottom)
were incubated with SpCas1 proteins. Each reaction was supplemented with
no metal (NM), EDTA, or various divalent ions. As a positive control, DNase I
was used to cleave the dsDNA substrates.its tetrameric structure and affinity to dsDNAs (Koo et al., 2012).
Recently, it has been shown that SpCsn2 associates with other
S. pyogenes Cas proteins including SpCas1 (Heler et al.,
2015), suggesting the formation of a multiprotein Cas complex
in type II CRISPR-Cas systems. When expressing C-terminal
(His)6-tagged SpCas1 together with untagged SpCsn2 in
E. coli BL21 (DE3) cells, we observed a co-purifying protein
following nickel-affinity chromatography, whose molecular
weight appears to be identical to that of SpCsn2, whereas the
untagged SpCsn2 alone did not bind to the nickel column (Fig-
ure S4). Mass spectrometry confirmed the identity of the co-pur-
ifying protein to be SpCsn2 (Table S3). These observations
suggest an interaction between SpCas1 and SpCsn2.
To confirm whether SpCas1 interacts directly with SpCsn2 to
form a complex, we performed experiments using separately pu-
rified SpCas1 and SpCsn2 proteins. We first used size-exclusion
chromatography to test and analyze the interaction between
SpCas1 and SpCsn2. The pre-incubated SpCas1 and SpCsn2
were eluted together with a shorter retention time than those of
the two individual proteins alone, implying the formation of the
SpCas1-SpCsn2 complex (Figure 5A). To assess the stoichiom-
etry of the complex formation, chromatography was performed
with increasing amounts of SpCas1 (Figure 5B). In this experi-
ment, we observed a decrease in retention time and an increase
in peak height for the complex until the molar ratio between
SpCas1 and SpCsn2 reached 1:1. This suggests that a
maximum of two SpCas1 dimers can bind to a single SpCsn2
tetramer. We also found that the complex became less stable
as the salt concentration was increased (Figure 5C), indicating74 Structure 24, 70–79, January 5, 2016 ª2016 Elsevier Ltd All rightsthat electrostatic interaction plays a crucial role in the formation
of the SpCas1-SpCsn2 complex.
We then performed ITC to more quantitatively investigate the
interaction between SpCas1 and SpCsn2 (Figure 5D). For the
ITC experiment, we used an N-terminal (His)6-maltose binding
protein (MBP)-tagged SpCas1 protein. Without the tag, which
did not interfere with the complex formation in size-exclusion
chromatography (Figure S5), SpCas1 precipitated under the
experimental conditions used for our ITC analysis. The dissocia-
tion constant (KD) between SpCas1 and SpCsn2 was deter-
mined to be 5.0 mM, and the binding stoichiometry (N) of the
SpCas1 dimer to the SpCsn2 tetramer was calculated to be
2 (Figure 5D). This is consistent with the results from the
size-exclusion chromatography analysis, suggesting that two
SpCas1 dimers can interact with one SpCsn2 tetramer to
assemble an octameric complex in solution.
Identification of the Binding Interface for SpCas1-
SpCsn2 Complex Formation
After determining the complex formation between SpCas1 and
SpCsn2, we evaluated the potential binding interface between
the two Cas proteins. To determine which domain of SpCas1
is involved in the interaction, we purified (His)6-MBP-tagged
N-terminal and untagged C-terminal domains of SpCas1 and
tested their interactions with SpCsn2 (Figure 6A). The untagged
N-terminal domain was not soluble in our experimental condi-
tions. In the size-exclusion chromatography assay, the SpCas1
N-terminal domain eluted earlier with SpCsn2 (Figure 6B),
whereas the retention time of the C-terminal domain was iden-
tical with and without SpCsn2 (Figure 6C). This suggests that
the interaction with SpCsn2 involves only the N-terminal domain
of SpCas1. It is also likely that the N-terminal end of the domain
does not directly participate in the formation of the complex,
since the (His)6-MBP tag at the N terminus did not interfere
with the interaction (Figure S5).
The availability of the SpCas1 and SpCsn2 crystal structures
led us to perform in silico docking simulations to predict the po-
tential binding interface and the overall structure of the SpCas1-
SpCsn2 complex more precisely. In the predicted complex
structure (Figure 7A), the N-terminal domains of SpCas1 are
involved in the interaction with the a/b domains of SpCsn2.
This is consistent with the size-exclusion chromatography anal-
ysis in which SpCsn2 interacts with the N-terminal domain of
SpCas1, but not with the C-terminal domain (Figure 6). Among
the interface residues, we concentrated on three lysine residues
(K14, K18, and K25) of SpCas1 (Figure 7B) because our size-
exclusion chromatography analysis showed that the complex
formation was sensitive to salt concentration (Figure 5C), sug-
gesting that electrostatic interactions are important. These lysine
residues are not conserved in type I Cas1 homologs (Figure 3A).
To experimentally test the in silico docking results, we purified
three SpCas1 mutants (K14A, K18A, and K25A), whereby one of
the three lysine residues is mutated to alanine, and measured
their interactions with SpCsn2 in size-exclusion chromatography
(Figure 7C, top). The K14A mutant did not interact with SpCsn2
at all, indicating that the K14 residue is crucial for the formation of
the SpCas1-SpCsn2 complex. The K25A mutant also displayed
significantly different behavior compared with wild-type (WT)
SpCas1. The K25A mutant complex was eluted considerablyreserved
Figure 5. Direct Interaction between
SpCas1 and SpCsn2
(A) Formation of the SpCas1-SpCsn2 complex in
size-exclusion chromatography. Separately puri-
fied SpCas1 (20 mM) and SpCsn2 (40 mM) were
used for the experiment. Elution fractions were
analyzed by SDS-PAGE.
(B) Determination of binding stoichiometry for the
complex by size-exclusion chromatography anal-
ysis. SpCsn2 was pre-incubated together with
increasing amounts of SpCas1, and analyzed by
size-exclusion chromatography.
(C) Effect of salt concentration on the complex
formation. Size-exclusion chromatography was
performed using increasing concentrations of
NaCl.
(D) ITC trace for SpCas1 binding to SpCsn2.
N-terminal (His)6-MBP-tagged SpCas1 was
added consecutively to the chamber containing
SpCsn2. The experimentally determined N and KD
values are also indicated. The untagged SpCas1
precipitated under the experimental conditions
used for ITC analyses.later than the WT complex, and a peak corresponding to the un-
bound SpCas1 mutant emerged, suggesting that the K25 resi-
due is important for its interaction with SpCsn2. On the contrary,
the K18A mutant showed a chromatogram similar to that of WT
SpCas1, with a slightly longer retention time for the complex.
This suggests that the K18 residue is the least important for com-
plex formation among the three lysine residues in SpCas1. In the
predicted complex structure, K14 and K25 of SpCas1 form the
core of the binding interface, while K18 is found near the rim of
the interface. It is also noteworthy that K18 is less conserved
than K14 and K25 in type II Cas1 homologs (Figure S2). K14 is
strictly conserved, and K25 is either conserved or mutated to
arginine in most type II Cas1 proteins.
From the results of the in silico docking simulation, we were
also able to identify SpCsn2 residues involved in the interaction
with SpCas1. In the complex model, two negatively charged
SpCsn2 residues (E23 and E199) in its a/b domains are in close
contact with the three lysine residues in SpCas1 (Figure 7B). To
further validate the in silico docking prediction, we generated
two SpCsn2 mutants (E23A and E199A) and tested their interac-
tion with WT SpCas1 through size-exclusion chromatography
(Figure 7C, bottom).While the E199Amutation resulted in a chro-
matogram essentially identical to that of WT SpCsn2, the E23A
mutant showed reduced affinity to SpCas1 compared with WTStructure 24, 70–79, January 5, 201SpCsn2. This indicates that the E23 resi-
due is involved in the interaction with
SpCas1 for complex formation. In fact,
E23, but not E199, is well conserved in
other Csn2 homologs (Figure S2).
Based on these results, we concluded
that the computational prediction for the
binding interface is valid, and the charged
residues at the interface participate in the
electrostatic interactions that form the
SpCas1-SpCsn2 complex. The conser-
vation of these charged residues sug-gests that the Cas1-Csn2 complex formation is likely a general
feature of type II CRISPR-Cas systems.
DISCUSSION
Cas1 is a universal Cas protein found in all three types of
CRISPR-Cas systems (Makarova et al., 2011). Although several
Cas1 proteins from type I CRISPR-Cas systems have been
described structurally and functionally (Babu et al., 2011; Kim
et al., 2013; Wiedenheft et al., 2009), homologs from other
CRISPR-Cas types have not been previously characterized.
The results presented here provide structural information for
SpCas1 in the S. pyogenes type II CRISPR-Cas system.
Despite similarities in domain folds, the crystal structure of
SpCas1 revealed a unique structural feature of a type II Cas1
protein that is distinct from the type I Cas1 homologs. It is
not uncommon that proteins of the same domain fold can
possess different multimerization interfaces as well as quater-
nary assemblies. For example, subunits of oligomeric hemoglo-
bins share the common globin fold, but display a variety of
structural patterns in their assemblages for mechanistic diver-
sity (Royer et al., 2001, 2005).
In the C-terminal domain of SpCas1, important structural dif-
ferences from the type I homologs were found to be related to6 ª2016 Elsevier Ltd All rights reserved 75
Figure 6. SpCsn2 Interacts with the N-Terminal Domain of SpCas1
(A) Schematic representation of the N- and C-terminal domains (Ntd and Ctd,
respectively) of SpCas1 used in the experiment. The (His)6-MBP-tagged
N-terminal domain of SpCas1 was used, since the untagged SpCas1 N-ter-
minal domain was not soluble under the condition used.
(B and C) Size-exclusion chromatography analysis for testing complex for-
mation using the SpCas1 N-terminal (B) and C-terminal (C) domains.the potential catalytic function. It seems that the extensive
dimerization interaction between the two C-terminal domains
of the SpCas1 dimer caused the structural rearrangement of
several residues within the C-terminal domains, including the
three conserved residues (Glu149, His205, and Glu220). In the
type I Cas1 structures, the side chains of these three conserved
residues were found within close proximity, presumably coordi-
nating a catalytic metal ion. However, in SpCas1 the histidine
residue was found distant from the two glutamate residues (Fig-
ure S3), and, in one monomer, the potential metal-binding site is
occupied by the side chain of Q208 from the other monomer
(Figure 4A). In addition, the unique conformational state of
SpCas1 resulted in the burial of potential metal-binding sites.
These data suggest that SpCas1 may not share the nuclease
function due to the impairment and/or inaccessibility of the
metal-binding site for catalysis.
Consistent with the structural analysis, our nuclease activity
assays showed that SpCas1 did not cleave any of the tested
nucleic acid substrates. We cannot exclude the possibility
that SpCas1 may require more specific nucleic acid substrates
and/or experimental conditions for its function as a nuclease.76 Structure 24, 70–79, January 5, 2016 ª2016 Elsevier Ltd All rightsHowever, it is also conceivable that our SpCas1 structure rep-
resents an inactive conformation and that the binding of other
factors may induce conformational switching to its catalyti-
cally active state. The idea of conformational activation is
intriguing, since it can serve as part of the molecular mecha-
nism for regulating nuclease activity of spacer acquisition
machinery.
To investigate this possibility, we tested the dsDNA nuclease
activity of SpCas1 in the presence of one or all of individually
purified SpCsn2, S. pyogenes Cas2 (SpCas2), and SpCas9
proteins, but did not detect any cleavage (Figure S3).
The (His)6-MBP tag, which was essential for solubilizing
SpCas2 under our experimental conditions, could interfere with
proper binding and/or conformational changes. A catalytically
functional multiprotein Cas complex might not be formed by
the in vitro reconstitution using the individually purified Cas pro-
teins. It is also possible that additional viral or endogenous
S. pyogenes factor(s) might be required for the conformational
switching and/or catalytic activity of SpCas1. It is noteworthy
that in the type II CRISPR-Cas systems, the processing of
crRNAs depends on the endogenous RNase III as well as Cas9
(Deltcheva et al., 2011).
In our predicted complex model, two SpCas1 proteins bind to
the diamond-shaped ring structure of SpCsn2 at two opposite
corners located farther away (Figure 7A). The distance between
the central hole of SpCsn2 and the active sites of the bound
SpCas1 dimers is 95 A˚, and that between the active sites of
the two SpCas1 dimers bound to the opposite corners is
190 A˚. Since Csn2 is known to bind dsDNAs through its central
hole (Arslan et al., 2013), it is difficult to imagine that SpCas1 can
reach the same dsDNA molecule bound to SpCsn2 in the com-
plex. It is more likely that SpCas1 and SpCsn2may bind to sepa-
rate dsDNAs or branched DNAs during spacer acquisition.
It is interesting to note that some type II CRISPR-Cas systems
contain longer Csn2 homologs (350 amino acids) than SpCsn2
(220 amino acids) (Chylinski et al., 2014). The crystal structure of
one of these long Csn2 proteins, Streptococcus thermophilus
Csn2 (StCsn2), displayed a tetrameric state, resulting in a dia-
mond-shaped ring structure, as seen in the short Csn2 proteins
such as SpCsn2 (Figure S6) (Lee et al., 2012). In addition, the
long StCsn2 structure revealed an extra C-terminal domain (res-
idues 266–350) in its subunits (Lee et al., 2012). These additional
C-terminal domains are tightly packed against each other at two
opposite corners of the diamond-shaped ring structure. They
make contact with the a/b domains of StCsn2 as the SpCas1 di-
mers bind to those of SpCsn2 in our in silico docking model. It
appears that the SpCas1 dimers, and the C-terminal domains
of the long StCsn2, interact with the same region of the dia-
mond-shaped ring in Csn2 structures. This suggests that the
long Csn2 proteins may interact with Cas1 using different bind-
ing interface(s). In fact, the glutamate residue (E23) of SpCsn2
involved in the interaction with SpCas1 is not well conserved in
long Csn2 homologs (Figure S6). It is also conceivable that the
long Csn2 homologs may not form complexes with Cas1 pro-
teins. In such cases, the extra C-terminal domains in the long
Csn2 proteins may take over, at least in part, the potential struc-
tural role(s) of Cas1 required for the short Csn2 proteins.
It has recently been reported that Cas9 associates with other
Cas proteins (Cas1, Cas2, and Csn2) in the S. pyogenes type IIreserved
Figure 7. Identification of the Putative
SpCas1-SpCsn2 Binding Interface
(A) In silico docking model of the SpCas1-SpCsn2
complex. SpCas1 is colored as in Figure 2, and
SpCsn2 is shown in blue.
(B) Close-up view of the putative SpCas1-SpCsn2
binding interface in the in silico docking model.
The charged residues involved in electrostatic in-
teractions between SpCas1 and SpCsn2 are an-
notated.
(C) Size-exclusion chromatography analysis of
SpCas1 (20 mM) and SpCsn2 (40 mM) mutant
proteins. WT, wild-type.CRISPR-Cas system, indicating the formation of a multiprotein
Cas complex composed of Cas1, Cas2, Csn2, and Cas9 (Heler
et al., 2015). It is likely that the SpCas1-SpCsn2 complex
described in this study might be a subcomplex of the larger
Cas complex. Although it is at present difficult to accurately
predict the architecture of the larger S. pyogenes Cas complex,
we were able to generate a model for the S. pyogenes Cas1-
Cas2-Csn2 subcomplex using the available information (Fig-
ure S7). First, a model for the SpCas1-SpCas2 complex was
created by homology modeling of SpCas2 and structure super-
position based on the crystal structure of the E. coli Cas1-Cas2
complex (Nunez et al., 2014), then it was combined with the
predicted SpCas1-SpCsn2 model structure to generate the
final model for the SpCas1-SpCas2-SpCsn2 complex. In this
model, SpCas2 and SpCsn2 do not overlap with each other
and bind to different regions in the N-terminal domain of
SpCas1.
Together with previous studies, our results reveal the struc-
tural diversity of the universal Cas1 protein and provide evidence
that a multiprotein Cas complex may function in the adaptation
stage of CRISPR-mediated immunity in type II CRISPR-Cas sys-
tems. Csn2, which can bind to DNAs through the central hole in
its diamond-shaped ring structure (Arslan et al., 2013), may
serve as a scaffold protein interacting directly with multiple
Cas proteins. A high-resolution structure of the Cas1-Csn2 com-
plex and the overall architecture of the larger multiprotein Cas
complex in type II CRISPR-Cas systems remain to be deter-
mined experimentally.Structure 24, 70–79, January 5, 201EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
The S. pyogenes cas1 gene was amplified by
PCR from S. pyogenes SF370 genomic DNA
and cloned into a pHMGWA vector that has an
N-terminal (His)6-MBP tag and a tobacco etch
virus (TEV) protease cleavage site (Busso et al.,
2005). E. coli BL21 (DE3) cells containing
these constructs were cultured in Luria-Bertani
medium at 37C until the optical density at
600 nm reached 0.7. The expression of SpCas1
was induced by the addition of 0.3 mM iso-
propyl-b-D-thiogalactopyranoside, followed by
incubation at 17C for 16 hr. The cells were har-
vested by centrifugation and resuspended in
lysis buffer (300 mM NaCl, 10% [w/v] glycerol,
5 mM b-mercaptoethanol [BME], 20 mM Tris-
HCl [pH 8.0]).After sonication and centrifugation, the supernatant was loaded onto a 5-ml
HisTrap HP column (GE Healthcare) pre-equilibrated with elution buffer
(300 mM NaCl, 10% [w/v] glycerol, 5 mM BME, 30 mM imidazole, 20 mM
Tris-HCl [pH 8.0]). After washing the column with the elution buffer, the bound
protein was eluted by applying a linear gradient of imidazole (up to 500 mM),
and was dialyzed against TEV proteolysis buffer (175 mM NaCl, 10% [w/v]
glycerol, 5 mM BME, 20 mM Tris-HCl [pH 8.0]). The (His)6-MBP tag was
cleaved by TEV protease and separated by using a 5-ml HiTrap Heparin HP
column (GE Healthcare). The protein was further purified using a HiLoad
16/60 Superdex200 column (GE Healthcare) equilibrated with size-exclusion
chromatography buffer (300 mM NaCl, 10% [w/v] glycerol, 2 mM DTT,
20 mM Tris-HCl [pH 8.0]). SpCsn2 was expressed and purified as described
previously (Koo et al., 2012).
Crystallization, Data Collection, and Structure Determination
For determination of the crystal structure of SpCas1, selenomethionyl protein
was expressed in E. coli BL21 (DE3) cells grown in M9 medium supplemented
with SeMet, as described previously (Mark et al., 2001). The protein was puri-
fied as described above for native SpCas1 protein. The selenomethionyl
SpCas1 crystals were grown at 20C by the hanging-drop method from
4.2 mg/ml protein solution in buffer (300 mM NaCl, 10% [w/v] glycerol,
2 mM DTT, 20 mM Tris-HCl [pH 8.0]) mixed with an equal amount of reservoir
solution (0.6/0.6 M Na/KH2PO4, 27% [w/v] glycerol, 130 mM HEPES [pH 7.0]).
The crystals were flash-frozen in liquid nitrogen without additional cryoprotec-
tive reagents.
Diffraction data were collected at the beamline 7A of the Pohang Accel-
erator Laboratory at 100 K. The diffraction images were processed using
HKL2000 (Otwinowski and Minor, 1997). Determination of selenium posi-
tions, density modification, and initial model building were performed using
Phenix (Adams et al., 2002). The structure was completed using alternate
cycles of manual fitting in Coot (Emsley and Cowtan, 2004), and refinement
in Phenix (Adams et al., 2002) and REFMAC5 (Murshudov et al., 1997). The6 ª2016 Elsevier Ltd All rights reserved 77
stereochemical quality of the final models was assessed using MolProbity
(Chen et al., 2010).
Activity Assay
Linearized pUC19 plasmids (100 ng) and PCR products containing the
S. pyogenes type II CRISPR sequence (200 ng) were incubated with SpCas1
(20 mM) in reaction buffer (100 mM KCl, 10% [w/v] glycerol, 1 mM DTT,
25 mM HEPES [pH 7.5]) at 20C for 2 hr. After Proteinase K treatment and
phenol-chloroform extraction, the reaction products from the linearized plas-
mids and PCR products were analyzed on 1% (w/v) and 2.5% (w/v) agarose
gels, respectively.
Analytical Size-Exclusion Chromatography
Analytical size-exclusion chromatography was performed on a Superdex 200
10/300 Gl column (GE Healthcare). The column was equilibrated with buffer
containing 150 mMNaCl, 1 mM DTT, and 20 mM Tris-HCl (pH 8.0), after which
sampleswere loaded onto the column at a flow rate of 0.5ml/min. Experiments
with varying salt concentrations were performed by applying different amounts
of NaCl to the column.
Isothermal Titration Calorimetry
ITC experiments were performed at 20C using aMicroCal iTC200 system (GE
Healthcare). 125 mMSpCsn2 in buffer (150 mMNaCl, 20 mM Tris-HCl [pH 8.0])
was titrated with 20 consecutive 2-ml injections of 1 mM (His)6-MBP-tagged
SpCas1. The Origin software (OriginLab) was used for processing and analysis
of the ITC titration data.
In Silico Docking Simulation
The dimer structure of SpCas1 was docked onto the tetramer structure of
SpCsn2 by applying symmetry restraints that ensure the binding interfaces
for the two monomers of SpCas1 are equivalent to each other. For each of
the two-fold axes of the SpCsn2 structure, 1,000 models were generated
by 20 Monte Carlo with minimization (MCM) (Li and Scheraga, 1987) calcula-
tions starting from each of 50 initial models generated by rotating the SpCas1
structure along the axis. For MCM, the hybrid energy that consists of a phys-
ics-based energy and a knowledge-based potential (Fleishman et al., 2011)
developed previously were used. The model with the best energy among the
largest cluster of the 1,000 models was subject to refinement by GalaxyRefine
(Heo et al., 2013) to further optimize overall orientation and interface flexibility.
Preparation of Mutant Cas Proteins
Constructs for SpCas1 and SpCsn2 mutants were generated using mis-
matched PCR primers. The mutations were confirmed by DNA sequencing.
The mutant proteins were expressed and purified as described for WT
proteins.
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The atomic coordinates and structure factors were deposited in the PDB (Ber-
man et al., 2000) with the accession code PDB: 4ZKJ.
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